A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy

Brain

Volumn 134, Issue 9, 2011, Pages 2677-2686

  Klopstock, Thomas ^a   Yu Wai Man, Patrick ^b,c   Dimitriadis, Konstantinos ^a   Rouleau, Jacinthe ^d   Heck, Suzette ^a   Bailie, Maura ^b,c   Atawan, Alaa ^b,c   Chattopadhyay, Sandip ^b,c   Schubert, Marion ^a   Garip, Aylin ^e   Kernt, Marcus ^e   Petraki, Diana ^f   Rummey, Christian ^f   Leinonen, Mika ^g   Metz, Günther ^f   Griffiths, Philip G ^b,c   Meier, Thomas ^f   Chinnery, Patrick F ^b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MUNICH   (Germany)

^f Santhera Pharmaceuticals   (Switzerland)

^g Santhera Pharmaceuticals ^*  (Sweden)

Author keywords

idebenone; LHON; mitochondrial disease; mitochondrial DNA; mitochondrial encephalomyopathy; optic atrophy; optic neuropathy

Indexed keywords

IDEBENONE; MITOCHONDRIAL DNA;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDERMOID CYST; FEMALE; GENE MUTATION; HUMAN; LEBER HEREDITARY OPTIC NEUROPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 80052959702     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr170     Document Type: Article

References (26)

1. Arden GB, Wolf JE. Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 2004; 88: 1180-5. (Pubitemid 39141380)
2. Baracca A, Solaini G, Sgarbi G, Lenaz G, Baruzzi A, Schapira AH, et al. Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol 2005; 62: 730-6. (Pubitemid 40656087)
3. Barboni P, Savini G, Valentino ML, Montagna P, Cortelli P, De Negri AM, et al. Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy. Ophthalmology 2005; 112: 120-6. (Pubitemid 40075330)
4. Barnils N, Mesa E, Munoz S, Ferrer-Artola A, Arruga J. Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy. Arch Soc Esp Oftalmol 2007; 82: 377-80.
5. Carelli V, Barboni P, Zacchini A, Mancini R, Monari L, Cevoli S, et al. Leber's Hereditary Optic Neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci 1998; 160: 183-8. (Pubitemid 28522546)
6. Carelli V, Valentino ML, Liguori R, Meletti S, Vetrugno R, Provini F, et al. Leber's hereditary optic neuropathy (LHON/11778) with myo-clonus: report of two cases. J Neurol Neurosurg Psychiatry 2001; 71: 813-6. (Pubitemid 33121930)
7. Cortelli P, Montagna P, Pierangeli G, Lodi R, Barboni P, Liguori R, et al. Clinical and brain bioenergetics imporvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997; 148: 25-31. (Pubitemid 27149521)
8. Grigsby SS, Vingrys AJ, Benes SC, King-Smith PE. Correlation of chromatic, spatial, and temporal sensitivity in optic nerve disease. Invest Ophthalmol Vis Sci 1991; 32: 3252-62.
9. Guy W. Clinical global impression. In: Guy W, editor. Assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare; 1976. p. 125-6.
10. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-Dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011; 6: e17963.
11. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet 1995; 57: 77-86.
12. Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, et al. Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci 2009; 50: 3112-5.
13. Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol 2009; 247: 137-42.
14. Man PY, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of leber hereditary optic neuropathy in the north East of England. Am J Hum Genet 2003; 72: 333-9. (Pubitemid 36194242)
15. Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet 1992; 340: 368-9.
16. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 2000; 20: 166-170.
17. Newman NJ, Biousse V, David R, Bhatti MT, Hamilton SR, Farris BK, et al. Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am J Ophthalmol 2005; 140: 407-15.
18. Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11 778 mutation. American Journal of Ophthalmology 1991; 111: 750-62.
19. Nikoskelainen EK, Huoponen K, Juvonen V, Lamminen T, Nummelin K, Savontaus M-L. Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology 1996; 103: 540-14.
20. Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, Da Costa J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 1995; 118: 319-37.
21. Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF. The epidemiology of mitochondrial disorders-past, present and future. Biochim Biophys Acta 2004; 1659: 115-20. (Pubitemid 39575497)
22. Subei AM, Eggenberger ER. Optical coherence tomography: another useful tool in a neuro-ophthalmologist's armamentarium. Curr Opin Ophthalmol 2009; 20: 462-6.
23. van den Bosch M, Wall M. Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method. Eye 1997; 11: 411-17. (Pubitemid 27344830)
24. Ventura DF, Gualtieri M, Oliveira AG, Costa MF, Quiros P, Sadun F, et al. Male prevalence of acquired color vision defects in asymptomatic carriers of Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci 2007; 48: 2362-70. (Pubitemid 351261318)
25. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
26. Zanna C, Ghelli A, Porcelli AM, Martinuzzi A, Carelli V, Rugolo M. Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and Endonuclease G. Apoptosis 2005; 10: 997-1007. (Pubitemid 41285578)